F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125;Tomografía por emisión de positrones con F-18-FDG en el diagnóstico de recurrencia del cáncer de ovario. Comparación con TAC y CA 125

Revista Espanola de Medicina Nuclear

Volumn 22, Issue 4, 2003, Pages 217-223

  Garcia Velloso M J ^a   Boan Garcia J F ^a   Villar Luque, L M ^a   Aramendia Beitia J M ^a   Lopez Garcia G ^a   Richter Echeverria J A ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

CA125; CTscan; FDG PET; Ovarian cancer; Recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE FREE INTERVAL; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; BLOOD; CARCINOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ERROR; EVALUATION; LUNG EMBOLISM; MEDIASTINUM CYST; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OVARY TUMOR; PATHOLOGY; RETROSPECTIVE STUDY; REVIEW; SCINTISCANNING;

ADULT; AGED; CA-125 ANTIGEN; CARCINOMA; COMBINED MODALITY THERAPY; DIAGNOSTIC ERRORS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MEDIASTINAL CYST; MIDDLE AGED; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PULMONARY EMBOLISM; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 0141992670     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/s0212-6982(03)72189-2     Document Type: Article

References (27)

1. Einhorn W, Nilsson B, Stovall K. Factors influencing survival in carcinoma of the ovary. Cancer 1985;55:2015-2019.
2. C Mendiola, C Gómez Martín, H Cortés-Funes. Cáncer de ovario. En: M González Baron. Oncología clínica 2. Patología especial. McGraw-Hill. Interamericana. Madrid, 1998;299-311.
3. Podczaski E, Manetta A, Kaminski P, et al. Survival of patients with ovarian epithelial carcinomas after second-look laparotomy. Gynecologic Oncology 1990;36:43-7.
4. Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecologic Oncology 1990;38:203-9.
5. Hoskins WJ, Rubin SC, Dulaney E, et al. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. Gynecologic Oncology 1989;34:365-71.
6. Hoskins WJ, Pérez CA, Young RC, eds. Epithelial ovarian cancer. In: Principles and practice of gynecologic oncology. Philadelphia JB. Lippincott Company, 1992.
7. Trampal C, Maldonado A, Sancho-Cuesta F, et al. Papel de la tomografia por emision de positrones (PET) en la sospecha de recidiva tumoral ante la elevacion serica de marcadores tumorales. Rev Esp Med Nucl 2000;19:279-87.
8. Makar AP, Kristensen GB, Bormer OP, et al. CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer. Gynecologic Oncology 1992;45:323-8.
9. Martí Climent J, Calvo R, Peñuelas I, García Velloso MJ, Arbizu J, Richter JA. Comparación del funcionamiento de un tomógrafo de emisores de positrones en 2D y 3D. Rev Esp Med Nucl 1997;16:225.
10. Barrington SF, Maisey MN. Skeletal muscle uptake of fluorine-18-FDG: effect of oral diazepam. J Nucl Med 1996;37:1127-9.
11. 18F]-fluoride. Appl Radiat Isot 1990;41:49-55.
12. 18F]-fluoro-2-deoxi-D-glucosa: consideraciones prácticas. Rev Esp Med Nucl 1997;16:18-25.
13. Cronin V, Galantowicz P, Nabi A. Development of oncology protocol using fluorine-18-FDG: one center's experience. J Nucl Med Technol 1997;25:66-69.
14. Yancik R. Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 1993;71:517-23.
15. Rustin GJ, Nelstrop AE, Bentzen SM, et al. Selection of active drugs for ovarian cancer based on CA125 and standard response rates in phase II trials. J Clin Oncol 2000;18:1733-9.
16. Geary M, Foley M, Lenehan P. Recurrent ovarian carcinoma diagnosis and second-line therapy. Ir-Med-J. 1995 Mar-Apr;88(2): 698-70.
17. Rigo P, Paulus P, Kaschten BJ y cols. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996;23:1641-74.
18. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623-48.
19. Bailet JW, Abemayor E, Jabour BA, Hawkins RA, Ho C, Ward PH. Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 1992;102:281-8.
20. Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 1988;61:1776-81.
21. Warburg O, Wind F, Neglers E. On the metabolism of tumors in the body. En: Warburg O, ed. Metabolism of tumors. London: Constable. 1930;254-70.
22. Reiman EM. Positron emission tomography. Arch Intern Med 1990;150:729-31.
23. Jimenez-Bonilla J, Moya-Garcia F, Zomeno-Rodriguez M, et al. Deteccion de recidiva en cancer de ovario mediante PET-FDG. Rev Esp Med Nucl 2001;20:128-9.
24. Graham M. Is quantiatation necessary for oncological PET studies? Eur J Nucl Med 2002;29:133-5.
25. Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW. Positron emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol 2001;82:17-21.
26. Schroder W, Zimny M, Rudlowski C, Bull U, Rath W. The role of 18F-fluoro-deoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer. Int J Gynecol Cancer 1999;9:117-22.
27. Israel O, Keidar Z, Iosilevsky G, et al. The fusion of anatomic and physiologic imaging in the management of patients with cancer. Seminars in Nuclear Medicine 2001;31:191-205.